Scarica l'app Stockscreener
2.85
5.17%
0.14
Dopo l'orario di chiusura:
3.01
0.16
+5.61%
Precedente Chiudi:
$2.71
Aprire:
$2.69
Volume 24 ore:
1.20M
Relative Volume:
0.93
Capitalizzazione di mercato:
$31.76M
Reddito:
$128.60K
Utile/perdita netta:
$-4.60M
Rapporto P/E:
-8.1429
EPS:
-0.35
Flusso di cassa netto:
$-3.74M
1 W Prestazione:
+9.20%
1M Prestazione:
+333.20%
6M Prestazione:
+98.61%
1 anno Prestazione:
+819.35%
Intervallo 1D:
$2.66
$3.05
Intervallo di 1 settimana:
$2.25
$3.40
Portata 52W:
$0.2528
$4.05
Nexalin Technology Inc Stock (NXL) Company Profile
Nome
Nexalin Technology Inc
Settore
Industria
Telefono
(832) 260-0222
Indirizzo
1776 YORKTOWN, HOUSTON
Nexalin Technology Inc Borsa (NXL) Ultime notizie
Nexalin regains Nasdaq compliance with bid price rule By Investing.com - Investing.com Australia
Nexalin regains Nasdaq compliance with bid price rule - Investing.com India
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th - GlobeNewswire
Nexalin Technology : Regains Compliance with Nasdaq Continued Listing Requirements Form 8 K - Marketscreener.com
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements - The Manila Times
LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
Nexalin technology's chief medical officer buys $1,095 in stock By Investing.com - Investing.com Canada
Nexalin technology's chief medical officer buys $1,095 in stock - Investing.com India
EXCLUSIVE: Nexalin Technology Says New Data Confirms Implantable Device Improves Cognitive Function, Restores Brain Activity in Alzheimer's Patients - AOL
Nexalin Technology Announces Landmark Study on Alzheimer's - GlobeNewswire
Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease - StockTitan
EXCLUSIVE: Nexalin Technology Says New Data Confirms Investigational Non-Invasive Neurostimulation Device Improves Cognitive Function, Restores Brain Activity in Alzheimer's Patients (UPDATED) - Benzinga
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
Pre-Market Gains For Nexalin (NXL) Driven By Upcoming Clinical Trial - Stocks Telegraph
Nexalin trials Halo neurostimulation device in traumatic brain injury - Yahoo Finance
NXLNexalin Technology, Inc. Latest Stock News & Market Updates - StockTitan
Nexalin Technology Announces Planned Clinical Trial - GlobeNewswire
Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership - The Bakersfield Californian
Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA - StockTitan
Mixed results for Nexalin’s transcranial alternating current stimulation trial - Yahoo Finance
New Study Shows Nexalin’s Deep Intracranial Frequency - GlobeNewswire
New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients - StockTitan
EXCLUSIVE: Nano-Cap Nexalin's Drug-Free Alternative For Alzheimer's Shows Improved Memory, Cognitive Function In Small Study - Benzinga
Nexalin Technology Inc [NXL] Investment Guide: What You Need to Know - Knox Daily
NXL: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs - GlobeNewswire
Nexalin Technology Inc’s latest rating changes from various analysts - Knox Daily
Nexalin Technology : HALO Global Regulatory Strategy Presentation - Marketscreener.com
Neta X Launch Date Revealed, Price Of IDR 400 Million? - VOI English
World of light and colour on its way to city centre - Newark Advertiser
NEXT Biometrics Expands in India with New Order - TipRanks
Business News | Content-sharing Startup Newzo Mobile App Gets Seed Funding by Concept PR Mumbai - LatestLY
Tetra Pak and NIFTEM Sign MoU to Advance Food Processing Innovation in India - ThePrint
Content-Sharing Startup Newzo Mobile App Gets Seed Funding By Concept PR Mumbai - Zee News
Nexalin Technology Welcomes New SVP Carolyn Shelton - TipRanks
This smallcap IT stock gave 191% returns in last one year, hits new all-time high; here's why - Upstox
Nexalin Technology Inc (NXL) Stock: A Year of Declines and Increases - The InvestChronicle
Daily Progress: Nexalin Technology Inc (NXL) Drop -10.32, Closing at 0.85 - The Dwinnex
Nexalin Technology Participates in Congressional Roundtable - GlobeNewswire
Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment - StockTitan
Nexalin Technology shareholders approve board, plan amendment - Investing.com India
Nexalin Technology shareholders approve board, plan amendment By Investing.com - Investing.com UK
Nexalin Technology Granted U.S. Patent For DBS Device - MPO-mag
Nexalin Technology Second Quarter 2024 Earnings: US$0.17 loss per share (vs US$0.11 loss in 2Q 2023) - Yahoo Finance
Nexalin Technology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Nexalin Technology announces executive departure By Investing.com - Investing.com Australia
Nexalin Technology announces executive departure - Investing.com
Nexalin Technology SVP Michael Nketiah Announces Resignation - TipRanks
Nexalin Technology : Discover Nexalin’s Neurostimulation Device Targeting Mental Health Disorders - Marketscreener.com
Nexalin Technology Inc Azioni (NXL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nexalin Technology Inc Azioni (NXL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Owens David | Chief Medical Officer |
Aug 13 '24 |
Buy |
0.95 |
1,000 |
950 |
147,793 |
| Owens David | Chief Medical Officer |
Jun 28 '24 |
Buy |
1.75 |
1,000 |
1,750 |
146,793 |
| Owens David | Chief Medical Officer |
Jun 18 '24 |
Buy |
0.71 |
1,619 |
1,149 |
145,793 |
| Owens David | Chief Medical Officer |
Jun 10 '24 |
Buy |
0.64 |
3,000 |
1,920 |
144,174 |
0.47%
1.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):